Dimensional Fund Advisors LP Has $16.13 Million Stake in Olema Pharmaceuticals, Inc. $OLMA

Dimensional Fund Advisors LP boosted its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 12.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,082,434 shares of the company’s stock after acquiring an additional 123,790 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Olema Pharmaceuticals were worth $16,134,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in Olema Pharmaceuticals by 8.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock worth $325,000 after buying an additional 987 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Olema Pharmaceuticals by 44.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after acquiring an additional 1,169 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Olema Pharmaceuticals by 13.8% during the fourth quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock worth $359,000 after purchasing an additional 1,740 shares during the period. Finally, Torren Management LLC acquired a new position in shares of Olema Pharmaceuticals during the fourth quarter worth $44,000. Institutional investors own 91.78% of the company’s stock.

Insider Buying and Selling at Olema Pharmaceuticals

In related news, Director Cyrus Harmon sold 12,500 shares of the business’s stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the transaction, the director owned 715,270 shares in the company, valued at $8,282,826.60. The trade was a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.56% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on OLMA. HC Wainwright restated a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Weiss Ratings downgraded Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Wall Street Zen lowered Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Finally, Guggenheim cut their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $44.10.

Olema Pharmaceuticals Stock Performance

Shares of Olema Pharmaceuticals stock opened at $12.05 on Friday. The company has a market cap of $1.05 billion, a P/E ratio of -5.97 and a beta of 2.03. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $11.26 and a two-hundred day moving average price of $15.95. Olema Pharmaceuticals, Inc. has a 1-year low of $4.47 and a 1-year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.52). As a group, analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.